The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.
(2009) In International Journal of Cancer 124. p.2361-2366- Abstract
- Keratoacanthoma (KA) is difficult to histologically distinguish from squamous cell carcinoma (SCC). Therefore, although KA is a benign self-resolving skin lesion, KA is commonly treated as SCC. Biomarkers to distinguish KA and SCC would thus be desirable. In search for specific markers, paraffin-embedded tissue samples from 25 SCC and 64 KA were arranged in a tissue microarray (TMA) and stained for immunologic cell-markers CD3, CD20 and CD68 as well as for proteins considered of relevance in tumorgenesis, namely NFkappaB/p65, IkappaB-alpha, STAT3, p53, TRAP-1, pRB, phosphorylated pRb, Cyld, p21, p16(INK4), Survivin, Bcl-xL, Caspase 3, Bak, FLK-1/VEGF-r2 and Ki-67. In addition, the tumors were tested for presence of human papillomavirus by... (More)
- Keratoacanthoma (KA) is difficult to histologically distinguish from squamous cell carcinoma (SCC). Therefore, although KA is a benign self-resolving skin lesion, KA is commonly treated as SCC. Biomarkers to distinguish KA and SCC would thus be desirable. In search for specific markers, paraffin-embedded tissue samples from 25 SCC and 64 KA were arranged in a tissue microarray (TMA) and stained for immunologic cell-markers CD3, CD20 and CD68 as well as for proteins considered of relevance in tumorgenesis, namely NFkappaB/p65, IkappaB-alpha, STAT3, p53, TRAP-1, pRB, phosphorylated pRb, Cyld, p21, p16(INK4), Survivin, Bcl-xL, Caspase 3, Bak, FLK-1/VEGF-r2 and Ki-67. In addition, the tumors were tested for presence of human papillomavirus by PCR. We detected that the two lesions differed significantly in expression of Bcl-xL which was present in 84% of the SCC compared with only 15% in the KA (p < 0.001). The lower expression of the antiapoptotic protein Bcl-xL in KA is consistent with a possible role of apoptosis in the regression of KA. (c) 2008 Wiley-Liss, Inc. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1289315
- author
- Vasiljevic, Natasa LU ; Andersson, Kristin LU ; Bjelkenkrantz, Kaj ; Kjellström, Christer ; Månsson, Henrik LU ; Nilsson, Elise LU ; Landberg, Göran LU ; Dillner, Joakim LU and Forslund, Ola LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Cancer
- volume
- 124
- pages
- 2361 - 2366
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000265353200013
- pmid:19165861
- scopus:64249086910
- pmid:19165861
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.24197
- language
- English
- LU publication?
- yes
- id
- af11b3be-50d8-49ac-97b3-82bcd9116d0f (old id 1289315)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19165861?dopt=Abstract
- date added to LUP
- 2016-04-04 08:56:13
- date last changed
- 2022-05-09 03:02:49
@article{af11b3be-50d8-49ac-97b3-82bcd9116d0f, abstract = {{Keratoacanthoma (KA) is difficult to histologically distinguish from squamous cell carcinoma (SCC). Therefore, although KA is a benign self-resolving skin lesion, KA is commonly treated as SCC. Biomarkers to distinguish KA and SCC would thus be desirable. In search for specific markers, paraffin-embedded tissue samples from 25 SCC and 64 KA were arranged in a tissue microarray (TMA) and stained for immunologic cell-markers CD3, CD20 and CD68 as well as for proteins considered of relevance in tumorgenesis, namely NFkappaB/p65, IkappaB-alpha, STAT3, p53, TRAP-1, pRB, phosphorylated pRb, Cyld, p21, p16(INK4), Survivin, Bcl-xL, Caspase 3, Bak, FLK-1/VEGF-r2 and Ki-67. In addition, the tumors were tested for presence of human papillomavirus by PCR. We detected that the two lesions differed significantly in expression of Bcl-xL which was present in 84% of the SCC compared with only 15% in the KA (p < 0.001). The lower expression of the antiapoptotic protein Bcl-xL in KA is consistent with a possible role of apoptosis in the regression of KA. (c) 2008 Wiley-Liss, Inc.}}, author = {{Vasiljevic, Natasa and Andersson, Kristin and Bjelkenkrantz, Kaj and Kjellström, Christer and Månsson, Henrik and Nilsson, Elise and Landberg, Göran and Dillner, Joakim and Forslund, Ola}}, issn = {{0020-7136}}, language = {{eng}}, pages = {{2361--2366}}, publisher = {{John Wiley & Sons Inc.}}, series = {{International Journal of Cancer}}, title = {{The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.}}, url = {{http://dx.doi.org/10.1002/ijc.24197}}, doi = {{10.1002/ijc.24197}}, volume = {{124}}, year = {{2009}}, }